Ensayo de fase II que analiza durvalumab en combinación con el tratamiento
endocrino en pacientes con cáncer de mama ER+/her2- aptas para tratamiento endocrino
neoadyuvante y que presentan infiltración de linfocitos T CD8+ tras 4-6 semanas de exposición a
inmunoatrayente.
Fabrice André, MD, PhD (Medicine Oncology Department, Goustave Roussy, Paris)
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Cookie | Duración | Descripción |
---|---|---|
_hjIncludedInSessionSample_2433519 | 2 minutes | Description is currently not available. |
FormsWebSessionId | 1 month | Description is currently not available. |
m | 1 year 1 month 4 days | No description available. |
MC1 | 1 year | No description available. |
RpsAuthNonce | 1 month | Description is currently not available. |
VISITOR_PRIVACY_METADATA | 5 months 27 days | Description is currently not available. |
Cookie | Duración | Descripción |
---|---|---|
_hjAbsoluteSessionInProgress | 30 minutes | Hotjar sets this cookie to detect a user's first pageview session, which is a True/False flag set by the cookie. |